长链非编码RNA在卵巢癌化疗耐药过程中的调控作用

卵巢癌是女性生殖系统三大恶性肿瘤之一,也是导致女性妇科恶性肿瘤相关死亡的主要原因之一。虽然包括手术和化疗在内的治疗方案取得一定疗效,但卵巢癌患者5年总体生存率仍不令人满意。一是由于多数卵巢癌早期无明显症状,诊断时已是晚期;二是归因于卵巢癌复发率及化疗耐药性的提升。降低卵巢癌患者死亡率的关键是早期诊断和治疗以及对化疗耐药的有效预测。研究与卵巢癌相关的基因和蛋白的表达模式对促进诊断相关生物标志物的产生至关重要,并为药物设计、治疗和耐药性提供新的研究靶点。近年来,长链非编码RNA(long non-coding RNA,lncRNA)的作用日益凸显。已在包括癌症在内的许多疾病中发现lncRNA的异常表达,但其在疾病病因学和生物学的确切作用尚不清楚。随着对卵巢癌发病机制的深入研究,已有报道lncRNA的异常表达与铂类/紫杉醇耐药有关。综述近年来lncRNA在卵巢癌化疗耐药方面的研究进展。

The Role of Long Non-Coding RNA in Chemotherapy Resistance of Ovarian Cancer

Ovarian cancer is one of the three malignant tumors of the female reproductive system and also one of the main causes of death related to gynecological malignancies.Although treatment regimens including surgery and chemotherapy,have shown some success,the 5-year overall survival rate of patients with ovarian cancer is still unsatisfactory.One reason is that most ovarian cancers are asymptomatic in the early stages and diagnosed late.The other is due to the increased recurrence rate and resistance to chemotherapy.The key to reducing mortality in patients with ovarian cancer is early diagnosis and treatment and effective prediction of chemotherapy resistance.Studying the expression patterns of genes and proteins associated with ovarian cancer is critical to promoting the production of diagnostic biomarkers and to providing new research targets for drug design,treatment and resistance.In recent years,long non-coding RNA(lncRNA)plays an increasingly important role.Abnormal expression of lncRNA has been found in many diseases,including cancer,but its exact role in the etiology and biology remains unclear.With the further study on the mechanism of ovarian cancer,it has been reported that abnormal expression of lncRNA is related to platinum/paclitaxel resistance.This paper reviewed the recent advances in the application of lncRNA in chemotherapy resistance of ovarian cancer.